Guardant Health (GH) Q2 Revenue Up 31%

Guardant Health (NASDAQ:GH), a precision oncology company specializing in advanced cancer diagnostics and screening, reported results for the second quarter of fiscal 2025 on July 30, 2025. The company delivered GAAP revenue of $232.1 million, which exceeded the analyst consensus estimate of $211.5 million. It also reported a Non-GAAP loss per share of ($0.44), ahead of expectations for a non-GAAP loss of ($0.73) per share. Both revenue (GAAP) and earnings (non-GAAP) came in ahead of expectations, marking another period of accelerated growth. The quarter was highlighted by strong test volume growth, a positive gross margin in its new Shield screening business, and upwardly revised financial guidance. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Guardant Health delivers blood- and tissue-based cancer tests for therapy selection, disease monitoring, minimal residual disease (MRD) detection, and early screening. Its flagship products include the Guardant360 family of liquid and tissue biopsy tests, Guardant Reveal MRD test, and the Shield blood test for colorectal and multi-cancer screening.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool